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he use of minimally invasive procedures to 
manage primary and metastatic liver can-
cer has become increasingly common with 
the rising incidence of hepatic malignancies. 
Radioembolization, also known as selective internal 
radiation therapy or radiation microsphere therapy, is a 
complex yet minimally invasive procedure that aims 
to selectively deliver high doses of internal radiation 
using an intra-arterial infusion of microspheres loaded 
with the radionuclide yttrium-90 (Y-90).1,2 Indications 
for Y-90 radioembolization include managing primary 
liver malignancies and metastatic disease of the hepatic 
parenchyma.3 Patient selection criteria is covered in 
the literature, and some radioembolic agents of choice 
currently include SIR-Spheres Y-90 resin microspheres 
(Sirtex Medical Inc.) and glass TheraSpheres (BTG 
International Ltd.).4,5  
OVERVIEW 
Radioembolization treatment is a two-stage outpa-
tient process: the preparation/mapping stage and the 
treatment stage. In our institutions, patients are carefully 
evaluated, often incorporating multidisciplinary evalua-
tion from medical oncology, surgical oncology, radiation 
oncology, transplant surgery, hepatology, and interven-
tional radiology. After clinical evaluation by intervention-
al radiology, appropriate patients are scheduled for an 
angiographic preradioembolization mapping procedure, 
with a treatment date preselected 7 to 10 days after the 
mapping procedure. 
The mapping procedure serves two distinct pur-
poses. First, delineation of the hepatic arterial anatomy 
is important for eventual dose delivery and to avoid 
nontarget delivery. Variant hepatic arterial anatomy 
is common and occurs in up to 45% of patients (see 
Case Report 1).6 Determining and isolating the hepatic 
arterial branches perfusing the tumor(s) can help avoid 
possible complications. In addition, this procedure may 
be used to exclude, by means of embolization, hepatico-
mesenteric collaterals. 
Second, assessment of hepatopulmonary shunt-
ing is vital to determine the eventual radiation dose 
given to the patient.7 The degree of shunting is esti-
mated through intra-arterial infusion of technetium-99 
m-labeled macroaggregated albumin (Tc-99m MAA) 
(4–5 mCi) and subsequent measurement of the lung and 
liver activity.5 Although presence of a hepatopulmonary 
shunt is not an absolute contraindication, the radiation 
dose to the lungs should not exceed 30 Gy in a single 
setting, and the cumulative dose to the lungs should 
not exceed 50 Gy. The MAA scan also helps identify 
potential extrahepatic uptake of Tc-99m MAA, and we 
routinely perform single photon emission computed 
tomography (SPECT)/CT rather than planar imaging 
because we prefer the extra anatomic detail it provides 
(as seen in Case Report 1).
We prefer to position the microcatheter in the same 
location between the mapping procedure and the treat-
ment, as we believe the information provided by the 
MAA scan is the most accurate depiction of the subse-
quent treatment. After the treatment, it is standard prac-
tice to obtain a bremsstrahlung SPECT scan. We often do 
not obtain bremsstrahlung SPECT scan because it typi-
cally does not change the treatment and can extend the 
patient’s time in the department. We routinely prescribe 
methylprednisolone and recommend continuation of a 
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proton pump inhibitor for at least 1 month after the pro-
cedure. We do not routinely prescribe antibiotic prophy-
laxis for patients after the procedure. Patients are sched-
uled for a clinic visit and a 1- to 3-month follow-up MRI or 
CT angiogram (CTA) of the abdomen for primary hepatic 
malignancies versus a positron emission tomography/CT 
for metastatic tumors to assess response to therapy. 
MAPPING STUDY AND EMBOLIZATION
In our practice, we have predominantly shifted toward a 
transradial approach (TRA) to gain access to the abdomi-
nal aorta, although we still utilize a transfemoral approach 
as needed, and choice of access site tends to be operator 
dependent. We use a 5-F Glidesheath Slender (Terumo 
Interventional Systems) via the left radial artery. The 
A:  A 55-year-old man with bilobar metastatic colorectal cancer. A digital subtraction angiogram of the celiac artery from a 
transradial approach using a 110-cm, 5-F Sarah catheter shows splenic and common hepatic arteries. The common hepat-
ic artery divides into the gastroduodenal and proper hepatic arteries. 
B:  A selective microcatheter angiogram of the proper hepatic artery shows normal opacification of the right hepatic 
artery status after coil embolization of the GDA (straight arrow). The right gastric artery is not visualized; however, there 
is lack of opacification of the lateral segment of the left hepatic lobe (block arrow) raising suspicion of the presence of a 
replaced left hepatic artery from the left gastric artery (also known as a gastrohepatic trunk). 
C:  A superselective angiogram of the left gastric artery shows replaced left hepatic artery arising (straight arrow) with 
hepatic parenchymal opacification. 
D:  The decision was made to redistribute the flow of the left hepatic lobe to the proper hepatic artery. The replaced left hepatic 
artery origin was embolized (straight arrow), and selective left gastric arteriography shows opacification of gastric branches. 
E:  Subsequent superselective angiography from the proper hepatic artery shows coils in the replaced left hepatic artery 
with immediate redistribution of the left hepatic lobe arterial supply (straight arrow) from the proper hepatic artery. 
Tc-99m MAA was infused from this position to cover the whole liver.
F:  Unexpectedly, although the subsequent SPECT/CT scan coronal reformat after Tc-99m MAA instillation shows coverage 
of the entire liver, there is significant deposition in the duodenum (white arrow). It was surmised that a supraduodenal 
artery branch was present, and it was not well visualized on the angiogram. 
G:  In order to avoid duodenal deposition, the decision was made to split the Y-90 treatment dose for administra-
tion. Nonsubtracted angiography performed during treatment shows a 6-F Ansel sheath (block arrow) from a femoral 
approach positioned in the common hepatic artery with two microcatheters positioned in the right and middle hepatic 
arteries (straight arrows). The lobar doses were administered in sequential fashion.
Case Report 1
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technical details of transradial access are discussed in the 
literature.8 In most cases, a 110-cm Sarah, Jacky, or tiger 
Optitorque catheter (Terumo Interventional Systems) and 
a 1.5-mm J-Tip Glidewire (Terumo Interventional Systems) 
or Bentson guidewire (Cook Medical) are used to traverse 
the subclavian artery and advance into the abdominal 
aorta to select the mesenteric vessels. If difficulty accessing 
the descending aorta is encountered due to a tortuous 
aortic arch, a 110-cm pigtail catheter and an exchange-
length, angled, stiff Glidewire can almost always navigate 
the tortuosity, which is then exchanged for the mesenteric 
selective catheter. There is some hindrance to cone beam 
CT use with TRA, which may require a learning curve for 
the physicians and technologists, but complex emboliza-
tion can routinely be done from this approach with the 
appropriate equipment.
A:  A 62-year-old woman with bilobar metastatic ocular melanoma. Digital subtraction angiography of the common 
hepatic artery shows conventional hepatic arterial anatomy with the presence of a right gastric artery arising from the left 
hepatic artery (arrow). 
B:  The GDA was subsequently embolized with a plug (straight arrow), and attempts to catheterize the right gastric artery 
were unsuccessful. Selective angiography of the left gastric artery (curved arrow) opacifies the right gastric artery origin 
through its collateralization and subsequently the right and left hepatic arteries. 
C:  The microcatheter tip was subsequently advanced to the right gastric artery via the left gastric artery connection, and 
angiography opacifies the right and left hepatic arteries from this position. 
D:  Coil embolization was then performed on the right gastric artery origin through the microcatheter placed from the left 
gastric artery.
E:  Subsequent superselective microcatheter angiography from the proper hepatic artery shows no further filling of the 
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Thorough angiography is necessary; however, we do 
not perform an aortography, because it is an unnecessary 
contrast dye load. All patients undergo cross-sectional 
imaging including a CTA or MRI of the abdomen, which 
should be studied carefully in advance. We always start 
with a superior mesenteric artery (SMA) arteriogram to 
assess for the presence of replaced or accessory hepatic 
arteries; however, a thin-cut CTA can delineate these 
vessels as well and can sometimes obviate the need for 
an SMA angiogram. The arteriogram is obtained at a 
rate of 4 to 6 mL/sec for 24 to 30 mL. This is allowed 
to extend into the venous phase to assess for patency 
of the portal vein. The celiac artery is then selectively 
catheterized to evaluate the hepatic arterial anatomy. 
A celiac arteriogram is obtained at rates of 4 to 5 mL/sec 
for 16 to 25 mL. If an SMA angiogram is not obtained, 
celiac angiography is performed in the venous phase 
to evaluate the portal vein. Subsequently, a 3-F micro-
catheter of choice (eg, Renegade Hi-Flo, Direxion [both 
Boston Scientific Corporation], or Progreat [Terumo 
Interventional Systems]) is used to perform superselec-
tive angiography of the common, right, and left hepatic 
arteries. Angiography of the common hepatic artery is 
performed at a rate of 3 to 4 mL/sec for 12 to 16 mL, 
and angiography of the right and left hepatic arteries is 
performed at a rate of 2 to 3 mL/sec for up to 12 mL. 
A selective left gastric arteriogram may be considered 
to evaluate for replaced or accessory left hepatic arter-
ies. Cone beam CT is used extensively in our practice to 
delineate the anatomy, including the arterial feeders for the 
tumor(s), and to assess treatment coverage of the liver. 
Depending on the lesion location and the arteries 
identified via angiography, prophylactic embolization 
of the supraduodenal, gastroduodenal (GDA), right 
gastric, accessory gastric, falciform, or inferior phrenic 
arteries may be performed. We prefer not to embolize 
the cystic artery, even when identified in the treatment 
zone, as the incidence of radiation-induced cholecystitis 
is low. Embolization of the right gastric artery may be 
performed by entering via the left gastric artery when it 
cannot be catheterized from its hepatic origin (see Case 
Report 2). Embolization is accomplished with either 
detachable or nondetachable coils and plugs. We typi-
cally use a combination of these embolic agents. Use of 
high-flow microcatheters has been associated with dif-
ficulty deploying some detachable coils, and familiarity 
with which kinds of coils can and cannot easily deploy 
through a given microcatheter is extremely beneficial. 
We believe the benefits of a high-flow microcatheter, 
which provides better diagnostic angiograms with higher 
flow rates and better opacification, outweigh the draw-
backs with coils. 
Being mindful of which vessels the microspheres 
could reflux into often guides us to which vessel may 
require embolization. If the right hepatic artery is the 
target vessel and the first vessel the microspheres 
would reflux into is the left hepatic artery, emboliza-
tion is typically not performed. Careful evaluation for 
the presence of the right gastric artery should be per-
formed when infusing Y-90 in the left hepatic artery. 
If therapy is being infused from the proper hepatic 
artery, the GDA and right gastric artery likely need 
to be embolized. When embolizing the GDA, the key 
aspect is to ensure embolization over a long length and 
back up to the origin of the vessel to minimize chances 
of recanalization. We have also had instances of col-
lateral formation from the distal hepatic arteries to 
the distal GDA when only the proximal portion of the 
GDA has been occluded. For this reason, we also do not 
embolize the GDA when we believe it is unnecessary, 
such as in a lobar treatment when the microcatheter 
can be placed distally, away from the GDA origin.9 We 
often prefer starting with soft detachable coils distally, 
such as Concerto coils (Medtronic), to understand the 
optimal coil sizes and ensure more precise placement. 
This step may be followed by detachable Interlock 
(Boston Scientific Corporation) coils or pushable coils 
such as Tornado or Nester coils (both Cook Medical), 
which have more body and thrombogenicity. We then 
often use detachable coils again when approaching 
the origin of the vessel to prevent extension into the 
hepatic artery. Microvascular plugs, such as the MVP 
microvascular plug (Medtronic) and the Amplatzer 
Vascular Plug 4 (St. Jude Medical, Inc.), can also be 
used to embolize the GDA. The right gastric artery 
can be embolized with coils or a microvascular plug. 
Completion angiography performed after embolization 
should not show any further flow. 
Small accessory left hepatic or right hepatic arter-
ies may be embolized to redistribute perfusion to the 
native left or right hepatic artery for a single microcath-
eter administration. However, one should be wary of 
attempting intrahepatic redistribution of perfusion with 
segment IV or other intrahepatic lobar segments, as pre-
dicting whether the left or right hepatic artery will take 
over the perfusion in these situations can be difficult.
LOBAR VERSUS WHOLE LIVER TREATMENT
In cases of primary hepatic malignancy, including 
hepatocellular carcinoma, we prefer segmental or lobar 
treatments, even with bilobar disease. As a result, the 
infusion microcatheter can be placed distally into either 
the right or left hepatic arteries. Lobar therapy often 
obviates the need for embolization of branch vessels 
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off the common hepatic artery. In cases of metastatic 
disease, particularly colorectal cancer, data from the 
SIRFLOX trial are based on whole liver Y-90 therapy.10 
Therefore, in metastatic disease with bilobar tumors, we 
perform both staged treatments (but mostly whole liver 
treatments), and this is dependent on operator prefer-
ence. For metastatic neuroendocrine disease, given the 
side effects we have seen from tumor cell death and 
secretion of peptides and hormones, we still opt for 
lobar treatments in bilobar disease.
If there is challenging hepatic anatomy where an 
infusion cannot be performed from the proper hepatic 
artery safely, the Y-90 dose can be split between two 
separate microcatheters, which are placed distally into 
the hepatic lobes. This may be done with sequential 
treatments in the same setting using a 5-F catheter and 
microcatheter that are deposed in between treatments. 
Or, we often use a 6-F Flexor Check-Flo Introducer 
Ansel 2 guiding sheath (Cook Medical) into the ostium 
of the celiac artery from a transfemoral approach, fol-
lowed by placement of two separate microcatheters 
deep into the right and left hepatic arteries so that each 
microcatheter can be infused temporally and then dis-
posed of at once. 
OUTCOMES
Several studies have demonstrated radioembolization 
therapy to be safe and effective in the treatment of pri-
mary and metastatic hepatic malignancies.11 Early analy-
sis of a prospective cohort of 20 patients treated with 
Y-90 therapy reported significant outcomes with respect 
to both survival and quality of life.12 Radioembolization 
has also been shown to be safe and effective in unresect-
able hepatocellular carcinoma, with 79% showing tumor 
response when percent reduction and/or tumor necrosis 
were used as a composite measure of tumor response.13 
With respect to metastatic disease from colorectal can-
cer, recent data from the landmark SIRFLOX trial demon-
strated statistically significant median liver progression-
free survival when Y-90 was used in conjunction with 
standard chemotherapy.14 However, no improvement 
in overall progression-free survival was identified when 
compared to chemotherapy alone. Combination of 
data from the SIRFLOX trial and two other trials is being 
awaited to evaluate overall survival in a large cohort of 
patients. In metastatic neuroendocrine tumors, a review 
of available literature demonstrates safe and effective use 
of radioembolization in liver-dominant disease.15 
CONCLUSION
Selective internal radiation therapy has been shown 
to be an effective outpatient therapy for patients with 
either primary hepatic malignancies or metastatic liver 
disease.11-15 A thorough angiographic mapping study 
with embolization of some of the major branches of 
the common hepatic and proper hepatic arteries is a 
major component of the two-stage process for Y-90 
therapy. Lobar or segmental therapy sometimes obvi-
ates the need for embolization in our recent experi-
ence; however, new users should be cautious, as the 
repercussions of nontarget delivery of Y-90 micro-
spheres can be significant.  n
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